🏥 L’Hospital de Bellvitge colidera un estudi per millorar el tractament contra el colesterol després d'un infart 🫀 L’estudi, desenvolupat conjuntament amb l’Hospital Álvaro Cunqueiro de Vigo i publicat aquest novembre a la prestigiosa revista Circulation, aporta noves

Primers casos del @VulnerableTrial a l’hospital Mutua de Terrassa. Dos pacients amb dues plaques magnifiques per l’estudi aleatoritzat i un tercer pel registre! Moltes gracies a les dres. Homs, Toledano i Fuertes i a tot l’equip d’HCA!

Online in @heart_bmj 3 year results form SUGAR Trial ! @rafa_romaguera Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial

Recta final para la inclusion del @VulnerableTrial con el paciente 500 del RCT aleatorizado. Ya quedan 100 para llegar a los 600 objetivo. Esta vez nos ha tocado en Bellvitge. Caso muy claro de una CF con ALM 2,5 mm2, carga placa 80%, arco lipido >300^ y capa fibrosa de 50 micras

🫀 EAPC–EACVI Consensus 2025: CAD Regression and Imaging Evaluation In this consensus document we perform another step forward towards modern cardiovascular medicine. In particular it emerges strongly the concept that Atherosclerosis should be tackled early, phenotyped

Cannot not share this 😅

Bad news for enthusiasts of left atrial appendage closure from #AHA25. CLOSURE-AF is not yet published, but reports from New Orleans indicate inferiority compared with best medical care (the trial was designed for non-inferiority, making this the most unexpected and unfavorable

We’re kicking off #XploringX1 to showcase what coronary physiology with One Angiogram, One Minute, One Platform is all about. X1-FFR is the only FDA-cleared single angiogram physiology technology, analyzing vessel flow and geometry to deliver results — with no wires, no drugs,

Microvascular Madrid Meeting #MMM25 📅26-27 November 📍Hospital Universitario de La Princesa, Madrid 🤓Don’t miss this opportunity @JovenesSec @ResiSec @secardiologia

https://t.co/vRC1tZMRjp

everyone is excited about DCB after Selution trial. but no inferiority margin was set at 50%. this means that even with 2.5% of events in DES group, DCB would have been still no inferior. in which other scenario we accept that a new treatment can be up to 50% less effective than

Yes! I’ve won the #AIvsHuman contest #TCT2025! I’m the #TopDog. Not easy to compete against @hahn_rt and @philippvstein …

Muchas gracias por la confianza. Ilusionado de formar parte de este equipo como nuevo presidente electo de @shci_sec @secardiologia Intentaremos estar a la altura de los grandes @belcid7 @StructuralBCN @teresabastante. @jmmoreiras q dejan el listón altísimo @pabl0salinas #JuanSR

The most anticipated trial at next #TCT2025 is SELUTION DeNovo. So let’s take a closer look. This study represents an important crossroads for drug-coated balloons (DCBs) in de novo lesions, since—apart from small vessels—the results so far have been far from impressive. Let’s

Todo listo para el #cursoOMG ! 10º aniversario. 👉🏻9 casos en vivo desde SantPau, VallHebron y Bellvitge. Kinoshita🇯🇵Azzalini🇮🇹🇺🇸 y los operadores nacionales +🔝 🎯Hotel Olivia Balmes - Barcelona 🗓️9-10 octubre https://t.co/FFcSPUMdAF

Debate! 📣 Intravascular imaging in percutaneous revascularization procedures. #recintervcardiol #AheadOfPrint 🚨 For an optimized and still selective approach. Helena Tizón https://t.co/CSWxen2df2 🚨For a more widespread approach. Eva Rumiz @EvaRumiz

Comparison accross ongoing #RCT for vulnerable plaques

#VPM2025 “The Vulnerable Cell” is being presented at the “Vulnerable Patient/Plaque Meeting”; we are trying to understand atherosclerosis from within the plaque by looking into the cellular inhabitants Join online, registration is free" https://t.co/XIVNwxzrhY @Ortega_Paz

A very interesting discussion about vulnerable plaque!

Registro español de hemodinámica y cardiología intervencionista. XXXIV informe oficial de la ACI-SEC (2024) #REC #Aheadofprint @teresabastante @StructuralBCN @jmmoreiras @belcid7